Navigation Links
Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
Date:2/11/2008

LAVAL, QC, Feb. 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer, and Mr. Gary Schmid, Chief Executive Officer of the new nutraceutical business, will present Neurochem's strategy at the 2008 BIO CEO & Investor Conference to be held at the Waldorf-Astoria, in New York (NY). The presentation will take place at 11:00 A.M. EST, in the West Foyer room.

The live Web cast of Neurochem's presentation (audio and visual) can be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NRMX&item_id=17. A replay of the presentation will begin one (1) hour after the actual presentation time, and will be available until February 20, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

For further information, please contact:

Lise Hebert, PhD,

Vice President, Corporate Communications

Tel: (450) 680-4572

lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
2. Neurochem to present at JPMorgan Healthcare Conference
3. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
4. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
5. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
6. Neurochem reports results for third quarter of fiscal 2007
7. U.S. Representatives Urge Critical Improvements in Prostate Cancer Detection
8. Covance to Present at UBS Global Healthcare Services Conference
9. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
10. Mark Wylie and Suzy Preston Hoover Bring The Biggest Loser Million Pound Tour, Presented by MSN, to Dadeland Mall
11. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... portfolio company, today announced it has acquired the assets of Frankfurt, Germany ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... physical therapist assistants, under direct supervision of a licensed physical therapist, to render ... receives a consultation and treatment plan from a licensed physical therapist (PT) and ...
(Date:12/5/2016)... ... 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and Dr. ... do not do their research and undergo cosmetic dermatology treatments from unqualified practitioners or ... a renaissance and every other month a new treatment or device is launched, promising ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading ... with The American College of Surgeons (ACS) to provide basic bleeding control instructor ... Control Basic” course is a pilot program that fulfills the intent of the ...
(Date:12/4/2016)... ... December 03, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... A Wine Tasting Event in New York City, with long-time partners The Paul ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PITTSBURGH , Dec. 5, 2016  Wellbridge Health and ... innovative digital health solutions to Medicare and Medicaid plan members ... effort targeted at the unique needs of this group of ... on social work philosophies to provide insight into members, daily ... , ...
(Date:12/5/2016)... WOONSOCKET, R.I. , Dec. 5, 2016 /PRNewswire/ ... CVS ) Research Institute and the U.S. ... the Assistant Secretary for Preparedness and Response (ASPR), ... showed that automated pharmacy notifications encourage patients ... a forecasted natural disaster. The study also affirms ...
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson ... global medical technology company, will demonstrate an enhanced technology ... management technologies, including the company,s leading Pyxis™ and Alaris™ ... Pharmacists (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 ...
Breaking Medicine Technology: